Detecting Prostate Cancer Treatment Resistance When Treatment Options Are Still Available
At BioQuoVadis we are dedicated to extending and enhancing the lives of people with prostate cancer.
PSA detects prostate cancer drug resistance in 1.5-2.5 years. Our test detects it in 24 weeks - before the cancer spreads.
BioQuoVadis is bringing to market 30 years of federally funded science with the first laboratory based liquid biopsy test for prostate cancer treatment resistance.
Unmet Need
There are 4 millon people living with prostate cancer in the US, with 350,000 new cases every year. 400,000 patients are currently on ADT hormone therapy - and most will develop treatment resistance within 2 years.
Today's standard of care has no effective test for treatment resistance. PSA measures tumor growth, not drug response. By the time resistance is detectable, disease has often progressed to metastasis.
40,000 men die every year from prostate cancer. Many because treatment resistance was caught too late.
Our Solution
The BioQuoVadis test identifies treatment resistance before tumor burden increases and before it is reflected in PSA.
Physicians can adjust therapy - switch treatment, escalate to chemotherapy, or enroll patients in a trial - while intervention still makes a difference.
Meet the Team
Experienced team bringing cancer diagnostics from lab to market.
Leszek Kotula, MD, PhD
Founder & Chief Science Officer
The world expert in ABI1, a tumor supressor and AR co-regulator
Harry L. Leider, MD, MBA
CEO & Chief Medical Officer
Seasoned Physician- Executive to Lead BioQuoVadis from Biomarker Innovation to Commercial Adoption
Christine Burke
CFO & COO
Experienced early-stage and regulated industry business executive and complex execution leader
Contact Us
